{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for lactic root_notes_note in Note (approximate match)
Status:
Investigational
Source:
NCT01038440: Not Applicable Interventional Completed Sudden Cardiac Death
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00942656: Not Applicable Interventional Completed Cardiovascular Disease
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Vaccenic acid (VA) (t11 octadecenoic acid) is a positional and geometric isomer of oleic acid (c9-octadecenoic acid), and is the predominant trans monoene in ruminant fats (50%–80% of total trans content). Dietary VA can be desaturated to cis-9,trans-11 conjugated
linoleic acid (c9,t11-CLA) in ruminants, rodents,
and humans. Hydrogenated plant oils are another source of VA in
the diet, and it has been recently estimated that this source
may contribute to about 13%–17% of total VA intake. In contrast to suggestions from the epidemiological studies,
the majority of studies using cancer cell lines (Awad et
al. 1995; Miller et al. 2003) or rodent tumors (Banni et al.
2001; Corl et al. 2003; Ip et al. 1999; Sauer et al. 2004)
have demonstrated that VA reduces cell growth and (or) tumor
metabolism. Animal and in vitro studies suggest that
the anti-cancer properties of VA are due, in part, to the in
vivo conversion of VA to c9,t11-CLA. However, several additional
mechanisms for the anti-cancer effects of VA have
been proposed, including changes in phosphatidylinositol
hydrolysis, reduced proliferation, increased apoptosis, and inhibition
of fatty acid uptake. In conclusion,
although the epidemiological evidence of VA intake
and cancer risk suggests a positive relationship, this is not
supported by the few animal studies that have been performed. The majority of the studies suggest that any health benefit
of VA may be conferred by in vivo mammalian conversion
of VA to c9,t11-CLA. VA acts as a partial agonist to both peroxisome proliferator-activated receptors (PPAR)-α and PPAR-γ in vitro, with similar affinity compared to commonly known PPAR agonists. Hypolipidemic and
antihypertrophic bioactivity of VA is potentially mediated
via PPAR-/-dependent pathways.
Status:
Investigational
Source:
NCT00894127: Phase 1/Phase 2 Interventional Completed Lung Cancer
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02097706: Phase 2 Interventional Recruiting Borderline Personality Disorder
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
N-Methyl-D-aspartic acid is an amino acid derivative acting as a specific agonist at the NMDA receptor, and therefore mimics the action of the neurotransmitter glutamate on that receptor. Unlike glutamate, NMDA only binds to and regulates the NMDA receptor and has no effect on other glutamate receptors (such as those for AMPA and kainate). NMDA receptors are particularly important when they become overactive during withdrawal from alcohol as this causes symptoms such as agitation and, sometimes, epileptiform seizures. NMDA is a water-soluble synthetic substance that is not normally found in biological tissue.
Status:
Investigational
Source:
NCT00229437: Phase 2 Interventional Completed Diabetic Neuropathies
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04258462: Phase 2 Interventional Recruiting Benign Kidney Neoplasm
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
USAN:DIATRIZOATE SODIUM I 125 [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
USAN:DIATRIZOATE SODIUM I 131 [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03041116: Phase 3 Interventional Terminated Pantothenate Kinase-Associated Neurodegeneration
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Phosphopantothenic acid is an amidoalkyl phosphate that is the 4-phosphate derivative of (R)-pantothenic acid. Phosphopantothenic acid is not permeable to cell membranes due to its anionic character, consistent with the observation that systemic administration of Phosphopantothenic acid does not restore CoA levels in cellular and mouse models
Status:
Investigational
Source:
NCT00095797: Phase 1 Interventional Completed Adult Acute Basophilic Leukemia
(2004)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
XK-469 (2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid) is a novel synthetic quinoxaline phenoxypropionic acid derivative. The R-isomer of XK-469 was approximately twice as effective as the S-isomer of XK-469R. R( )-isomers induce reversible protein DNA crosslinks in mammalian cells. It acts as a selective topoisomerase IIβ inhibitor. A phase I study was performed to determine the safety and pharmacokinetics of XK-469, (R)- in patients with various neoplasms.